跳至主要内容
临床试验/NCT05376670
NCT05376670已完成不适用

Patient Satisfaction and Long-term Safety of Intravesical Aminoglycoside Instillations in UTI Prevention

Leiden University Medical Center1 个研究点 分布在 1 个国家目标入组 44 人开始时间: 2022年4月20日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
44
试验地点
1
主要终点
Treatment satisfaction regarding intravesical aminoglycoside instillations (IAI)

研究概览

简要总结

Antimicrobial prophylactic treatment of recurrent UTI is limited by emerging resistance, antibiotic allergies and intolerances. Intravesical aminoglycoside instillations (IAI) have been shown to reduce recurrence rate, without a short-term decline in kidney function or hearing. Thus far, treatment satisfaction has not yet been assessed, while this may play an important role in treatment adherence and persistence. Moreover, there is no data on the long-term safety of IAI, e.g. regarding the development of (pre)malignant bladder lesions.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • Currently receiving or having received (no minimal duration) continuous or post-coital IAI (gentamicin, tobramycin or amikacin) for recurrent UTI prophylaxis and treatment

排除标准

  • Exclusively receiving IAI for 'on-demand' treatment of UTI and not prophylactic purposes
  • Receiving IAI as suppressive therapy for chronic prostatitis
  • Presence of a chronic indwelling catheter
  • Patient has objected to the use of his/her data
  • Inability to provide informed consent

结局指标

主要结局

Treatment satisfaction regarding intravesical aminoglycoside instillations (IAI)

时间窗: 1 year

Measured with Treatment Satisfaction Questionnaire for Medication version II (TSQM-II), value ranging from 0 to 100 (with a score of 100 indicating the highest treatment satisfaction)

次要结局

  • Number of UTI recurrences that are treated with IAI alone (no systemic antimicrobial therapy)(First 6 months of IAI)
  • Number of patients that wish to (dis)continue IAI(6 months after initiation of IAI)
  • Proportion of patients that have a UTI episode caused by the same MDRO uropathogen as before start of IAI(6 months after initiation of IAI)
  • Number of UTI recurrences(First 6 months of IAI)
  • Time to first UTI recurrence after initiation of IAI(First 6 months of IAI)

研究者

发起方
Leiden University Medical Center
申办方类型
Other
责任方
Principal Investigator
主要研究者

Manu Bilsen, MD

MD, PhD student, Department of Infectious Diseases, Principle Investigator

Leiden University Medical Center

研究点 (1)

Loading locations...

相似试验